Avidity Biosciences has released answers to frequently asked questions about their Managed Access Program (MAP) for individuals with Duchenne who are amenable to exon 44 skipping and meet clinical criteria.
Learn more about eligibility and access:
The post Avidity Biosciences Managed Access Program (MAP) – Frequently Asked Questions appeared first on CureDuchenne.